- Conditions
- Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection, Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types
- Interventions
- Not listed
- Lead sponsor
- TScan Therapeutics, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana • Morristown, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 7,353
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Complete DiGeorge Anomaly, DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Syndrome
- Interventions
- Cultured Thymus Tissue
- Biological
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- Not listed
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cervical Cancer
- Interventions
- Flocked swab paired with Roche Cobas 4800
- Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Seattle, Washington
- Conditions
- Multiple Myeloma
- Interventions
- VAD, High-Dose cyclophosphamide, Hemopoietic stem cell procurement, EDAP, Autologous Hemopoietic Stem Cell Transplant 1, Autologous Hemopoietic Stem Cell Transplant 2, Maintenance
- Drug · Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2015
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Stillbirth, Placental Insufficiency
- Interventions
- Data Collection Throughout Pregnancy and Delivery
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 15 Years to 50 Years · Female only
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- GMA161
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Diego, California • Bethesda, Maryland + 3 more
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- iCura COVID-19 Antigen Rapid Home Test, RT-PCR Test
- Device · Diagnostic Test
- Lead sponsor
- New Day Diagnostics
- Network
- Eligibility
- 2 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Anaheim, California • Knoxville, Tennessee
- Conditions
- Gallbladder Cancer, Liver Cancer, Bile Duct Cancer
- Interventions
- questionnaires
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Primary Mediastinal Large B-Cell Lymphoma, Small Lymphocytic Lymphoma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma
- Interventions
- Avelumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 50
- States / cities
- Irvine, California • La Jolla, California • Los Angeles, California + 39 more
- Conditions
- Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent High Grade B-Cell Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory High Grade B-Cell Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refactory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Non-Hodgkin Lymphoma
- Interventions
- Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate, Echocardiography, Multigated Acquisition Scan, Biopsy, Pheresis, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
- Biological · Drug · Procedure
- Lead sponsor
- Sumithira Vasu
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Columbus, Ohio
- Conditions
- COVID-19, Influenza
- Interventions
- GRIP Electronic Diagnostic Chip, Laboratory-based nucleic acid amplification tests (NAATs)
- Device · Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Advanced Cancers
- Interventions
- Questionnaire and Review Session
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia
- Interventions
- Questionnaire
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 4,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Panitumumab, Sotorasib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 180
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 135 more
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 9 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Milwaukee, Wisconsin
- Conditions
- Cancer, Therapy-Related
- Interventions
- Registry
- Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2040
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Neural Tube Defects, Folic Acid Deficiency, Fortification
- Interventions
- Salt with folic acid and iodine
- Dietary Supplement
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Nutrition Education, Dietary Counseling, and Cooking
- Behavioral
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 13 Years to 21 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Postoperative Complications, Alcohol Use Disorder
- Interventions
- Blood Draw
- Other
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 21 Years to 79 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension Associated With Connective Tissue Disease, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder), Pulmonary Arterial Hypertension of Congenital Heart Disease, Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension
- Interventions
- Saliva sample, Health surveys
- Genetic · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Piscataway, New Jersey
- Conditions
- Neurogenic Bladder Disorder, Lower Urinary Tract Disorder, Urinary Tract Infection (Diagnosis)
- Interventions
- urine Resazurin Reduction Ratio, USQNB
- Diagnostic Test · Other
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Advanced Cancers, Pain
- Interventions
- Cordotomy, Pain/Symptom Questionnaire, Sharpness Sensory Testing, Heat Pain Sensory Testing
- Procedure · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Refractory Melanoma, Unresectable Melanoma
- Interventions
- Rigosertib, Pembrolizumab, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy
- Drug · Biological · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee